These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26893860)

  • 1. Genetic alterations in lung adenocarcinoma with a micropapillary component.
    Furukawa M; Toyooka S; Ichimura K; Yamamoto H; Soh J; Hashida S; Ouchida M; Shien K; Asano H; Tsukuda K; Miyoshi S
    Mol Clin Oncol; 2016 Feb; 4(2):195-200. PubMed ID: 26893860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.
    Zhu J; Cai L; Yang H; Wen Y; Wang J; Rong T; Shao J; Zhang L
    Thorac Cancer; 2014 Sep; 5(5):411-6. PubMed ID: 26767032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
    Wong DW; Leung EL; So KK; Tam IY; Sihoe AD; Cheng LC; Ho KK; Au JS; Chung LP; Pik Wong M;
    Cancer; 2009 Apr; 115(8):1723-33. PubMed ID: 19170230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
    Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
    Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of
    Jia X; Qian R; Zhang B; Zhao S
    J Thorac Dis; 2016 Oct; 8(10):2682-2688. PubMed ID: 27867542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.
    Li H; Hu H; Wang R; Pan Y; Wang L; Li Y; Zhang Y; Ye T; Zhang Y; Li B; Shen L; Sun Y; Chen H
    Onco Targets Ther; 2014; 7():513-24. PubMed ID: 24729716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages.
    Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2013 Jul; 81(1):53-9. PubMed ID: 23632273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study.
    Yang J; Li Y; Ma B; Xie H; Chen L; Gao X; He W
    Transl Cancer Res; 2020 Dec; 9(12):7562-7571. PubMed ID: 35117356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.
    Zhao M; Zhan C; Li M; Yang X; Yang X; Zhang Y; Lin M; Xia Y; Feng M; Wang Q
    J Thorac Dis; 2018 Jan; 10(1):398-407. PubMed ID: 29600072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.
    Doval D; Prabhash K; Patil S; Chaturvedi H; Goswami C; Vaid A; Desai S; Dutt S; Veldore V; Jambhekar N; Mehta A; Hazarika D; Azam S; Gawande S; Gupta S
    Onco Targets Ther; 2015; 8():117-23. PubMed ID: 25609979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driver mutation profiles and clinicopathological correlation in pulmonary adenocarcinoma with a micropapillary component.
    Zhang J; Sun J; Zhang Z; Wang A; Liang X; Lu J; Liang Z
    Hum Pathol; 2019 Mar; 85():242-250. PubMed ID: 30465798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
    Wang WT; Li Y; Ma J; Chen XB; Qin JJ
    Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer.
    Wen M; Wang X; Sun Y; Xia J; Fan L; Xing H; Zhang Z; Li X
    Onco Targets Ther; 2016; 9():1989-95. PubMed ID: 27103824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
    Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
    Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.